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INTRODUCTION
Quinolones are broad-spectrum antibiotics commonly used in the treatment of human and animal infections (Lu et al. 2015) . With the increased use of quinolones, the prevalence of bacterial resistance has steadily grown (Malorny, Schroeter and Helmuth et al. 1999) . Outbreaks caused by quinolone-resistant bacteria have been reported in the United States, Japan, the Netherlands and other regions (Helms et al. 2005) , and the antimicrobial resistance prevalence rate against quinolones has been shown to be high in clinical isolates from China (Dou et al. 2016; Gong et al. 2016; Zhu et al. 2017) . As such, the prevalence of quinolone resistance has drawn worldwide attention.
The target for quinolone drugs in E. coli and other Gram negative bacteria is the DNA gyrase and topoisomerase IV (Hooper 1999; Hooper 2001a Hooper , 2001b . The most common and most important mutations causing resistance are located in the quinolones resistance region (QRDR) of the gyrA and parC genes. The mutations in gyrA resulting in amino acid changes at positions 83 and 87 are the most frequent cause of resistance (Hooper 1999 (Hooper , 2001b Michael et al. 2006) . These amino acids are located near the active sites of DNA gyrase along with a tyrosine residue that interacts with the broken DNA strand during the topoisomerase reaction. Mutations in this active site may alter the binding of quinolones, thereby reducing the organism's susceptibility to the drug (Willmott and Maxwell 1993) . While numerous studies have shown the association between gyrA mutations and bacterial resistance to quinolone drugs, few studies investigated the causal role of gyrA mutation in quinolone resistance.
In this study, 818 clinical isolates of E. coli were tested for their susceptibility to a quinolone panel consisting of ciprofloxacin, enrofloxacin and nalidixic acid. PCR and DNA sequencing was performed to determine the gyrA mutations in these isolates. Furthermore, CRISPR/Cas9 was used to generate gyrA mutations in quinolone susceptible and resistant E. coli isolates to compare their activity.
METHODS

Bacterial isolates
In this study, we investigated 818 E. coli clinical isolates archived in the Veterinary Microbiology Laboratory of the College of Veterinary Medicine, Yangzhou University. These isolates were recovered from lung and liver of chickens (n = 644), lung, spleen and liver of pigs (n = 113), and milk of cows (n = 61) in Jiangsu province from 2004 to 2012 (Yassin et al. 2017) .
Antimicrobial susceptibility testing
The antimicrobial susceptibility profile of each of the E. coli isolates was determined against a quinolones panel using the agar disk diffusion method according to the Clinical Laboratory Standard Institute guidelines (CLSI 2015) and the clinical break points as the cut-off values. E. coli ATCC 25922 was used as control strain.
FRET-qPCR
The DNAs of the E. coli isolates were extracted with High Pure PCR Template Preparation Kit (Roche Diagnostics GmbH, Mannheim, Germany) following the manufacturer's protocol. The E. coli FRET-qPCR targeting the gyrA gene was performed as described before (Shaheen et al. 2009 
Editing of E. coli gyrA gene by CRSPR/Cas9
Plasmids used in this study (pCas9, pCRISPR and pKD46) were kindly provided by Prof. Guoqiang Zhu from College of Veterinary Medicine, Yangzhou University of China. The sgRNA1 and sgRNA2 were designed in www.crispr.mit.edu to induce gyrA mutations (nucleotide 248 C to T; nucleotide 259 G to T) ( Table 1) . Donor DNA for the gene mutation was synthesized by GenScript (Nanjing, China) ( Table 2 ). Plasmid pCas9 was electroporated into electrocompetent E. coli ATCC 25922 and isolates selected on agar plates containing chloramphenicol (34 μg/ml). The pKD46 plasmid was electroporated into competent E. coli ATCC 25922 containing pCas9 and screened on ampicillin (100 μg/ml) agar plates. Finally, the pCRISPR-FR plasmid and donor DNA were co-transferred into competent E. coli ATCC 25922 containing pCas9 and pKD46 plasmids and screened on a ciprofloxacin (0.01 μg/ml) containing plates ( 
Determination of bacterial growth
The growth rates of E. coli strains were monitored by measuring their OD 600 values in the LB medium at 1-h interval for 16 h.
Statistical analysis
All statistical analyses were performed with the Statistica 7.0 software package (StatSoft, Inc., Oklahoma, USA). Differences at P ≤ 0.05 were considered statistically significant.
RESULTS
Quinolones susceptibility testing of E. coli isolates
Overall, 77.1% of the E. coli isolates (631/818) were resistant to nalidixic acid, higher than ciprofloxacin (51.1%, 418/818) and enrofloxacin (49.8%, 407/818) (P < 10 −4 ) ( Table 3) .
Association of gyrA mutation and quinolones resistance
We identified seven nucleotide mutation sites at the positions 248, 255, 259, 260, 261, 273 and 300 in the gyrA ( Fig. 2 Table 2 , Supporting Information). Among six types of amino acid changes in positions 83 and 87, changes in leucine (83) and asparagine (87) were observed in 49.3% of the isolates (403/818). These isolates were predominantly resistant to all three types of quinolones (nalidixic acid, 97.3%; ciprofloxacin, 88.6%; enrofloxacin, 87.4%) ( Fig. 3; Table 3 , Supporting Information). Isolates with changes in amino acids 83 and/or 87 were highly resistant to nalidixic acid (97.1% to 100%) ( Fig. 3; Table 3 , Supporting Information). In this study, we found that 52.5% of the 818 E. coli isolates had double-site mutations at amino acids 83 and 87, showing resistance to nalidixic acid (97.6%), ciprofloxacin (88.8%) and enrofloxacin (87.4%), while a single mutation at codon 83 or 87 has no affect upon the organism's susceptibility to ciprofloxacin or enrofloxacin.
Change in resistance to quinolones due to CRISPR/Cas9-generating gyrA mutations
The CRISPR/Cas9 was performed to change C into T (position 249), and/or from G to T/A, and this resulted in strains E. coli ATCC 25922 S83L, E. coli ATCC 25922D87Y, E. coli ATCC 25922 S83L & D87Y (Fig. 4, Supporting Information) . Quinolone resistant E. coli S462231 L83S was created by a mutation at nucleotide 249 of E. coli S462231 (Fig. 4, Supporting Information) .
E. coli ATCC 25922 was susceptible to ciprofloxacin, enrofloxacin and nalidixic acid, while the mutants E. coli ATCC 25922 S83L, E. coli ATCC 25922D87Y, E. coli ATCC 25922 S83L & D87Y, were resistant to nalidixic acid. The mutant E. coli S462231 L83S was susceptible to ciprofloxacin and enrofloxacin but showed intermediate resistance to nalidixic acid (Table 4, Supporting Information; Table 5 , Supporting Information). There was no significant difference between the growth Changes in amino acids caused by gyrA mutation are associated with resistance to quinolones. In wild type E. coli, the 83rd and 87th amino acid are Ser (serine) and Asp (aspartic acid), respectively. Mutations in the gyrA gene result in changes in amino acids (in red font). Panel A indicates the percentages of E. coli isolates in this study without or with changes in amino acids. Panel B demonstrates resistance to ciprofloxacin, enrofloxacin and nalidixic acid associated with changes in amino acid.
rates of ATCC 25922, E. coli S462231 and the four generated mutants.
DISCUSSION
A wide variety of tools for targeted gene editing are available for E. coli including homologous recombination and group II intron retrohoming (Enyeart et al. 2013; Esvelt et al. 2013) . Among all the methods for generic editing in E. coli, only the singlestranded-DNA-based gene modification mediated by λ-Red was further developed as a multiplex genome editing tool, known as multiplex automated genome engineering (MAGE) (Wang et al. , 2011 . However, the short ssDNA oligonucleotidemediated MAGE faces challenges regarding targeted multiple gene insertions over a certain length ). Recently, the CRISPR-Cas9 system was used to apply allelic exchange in E. coli with efficiency as high as 65% (Jiang et al. 2013) . In this study, the CRISPR/Cas9 system was employed to verify the causal role of gyrA mutation in the quinolone resistance in E. coli.
While the antimicrobial resistance prevalence rate to fluoroquinolones in E. coli isolates in 1990s was less than 10% (Song et al. 2009) , it has increased to as high as 68% in 2005 and 2012 as demonstrated by the China CHINET drug resistance monitoring network (Wang et al. 2006) . In this study, we showed that the prevalence of quinolone resistance in animal pathogenic E. coli isolates obtained between 2004 and 2012 in China was 77.1% for nalidixic acid, 51.1% for ciprofloxacin and 49.8% for enrofloxacin. This is in sharp contrast to the antimicrobial resistance prevalence rate to fluoroquinolones in other countries. No ciprofloxacin resistance was found in E. coli from poultry in Australia (Obeng et al. 2012) , or in South Korea, where the prevalence of resistance in E. coli was as low as 29.8% for nalidixic acid and 10.8% for ciprofloxacin between 2006 and 2008 (Lee, Shin and Lee 2014) .
The amino acids codons 83 and a double mutation of codons 83 and 87 have been reported to be associated with bacterial resistance to quinolone drugs (De la Fuente et al. 2007) . In this study, 73.3% of the 818 E. coli strains were found to have the gyrA gene mutation at nucleotide 248 (C to T), resulting in an amino acid change from serine to leucine at position 83. This is in agreement with the report from Fisher et al. (1989) .
In this study, the genetic mutations were introduced to generate changes in amino acids 83 and/or 87 of the ATCC strains and a clinical strain, and the features of their resistance to quinolones were completely reversed. While previous study demonstrated low frequency of spontaneous mutations caused by ciprofloxacin incubation in E. coli (Jaktaji and Mohiti 2010) , future study should be provided to determine the spontaneous mutations during the fluoroquinolone incubation of this CRISPR/Cas9 experimental process. Our work shows that CRISPR/Cas9 system can be successfully used for target gene mutation research to investigate the bacterial resistance mechanism.
Resistance to quinolones described in this study is mainly mediated by mutations in gyrA and parC (Drlica et al. 2009 ). In addition, bacteria can also become resistant by horizontal gene transfer or other forms of exchange of genetic information by de novo cellular adaptation at the gene expression level (Händel et al. 2014) . Bacterial resistance to antimicrobials is brought by a complex interaction of cellular processes (Händel et al. 2014; Hughes et al. 2017) , involving adaption of expression levels and mutations. The quantitative adjustment of cellular processes at different levels facilitates the rapid acquisition of antimicrobial resistance.
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